Immunological aspects of combined chemotherapy and immunotherapy with HPV16 E6/E7 Synthetic Long Peptide vaccination in patients with advanced cervical cancer.
Completed
- Conditions
- cancer of the cervixcervical cancer10038594
- Registration Number
- NL-OMON36470
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
- Patients should be at least 18 years of age;
- Patients should be able and willing to provide informed consent;
- Patients with a diagnosis of histologically confirmed cervical cancer that is clinically and/or radiologically proven advanced, recurrent or metastatic for whom no curative treatment (surgery or radiotherapy) options are available;
- Patients scheduled for standard chemotherapy with Carboplatin / Paclitaxel;
Exclusion Criteria
For all patients (first and second cohort) the following exclusion criteria apply:
- Any condition that in the opinion of the treating physician(s) is likely to jeopardise the well-being of health status of the patient;
- Another active malignancy
- Positive test result for HIV
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>• The time related immune response during and after standard chemotherapy in<br /><br>patients with advanced, recurrent or metastatic cervical cancer;<br /><br>• The time and treatment related response to an HPV16 Synthetic Long Peptide<br /><br>(SLP) immunization in cervical cancer patients, after completion of the<br /><br>standard chemotherapy.</p><br>
- Secondary Outcome Measures
Name Time Method <p>N/A</p><br>